The bacterially produced metabolite violacein is associated with survival of amphibians infected with a lethal fungus.
The disease chytridiomycosis, which is caused by the chytrid fungus Batrachochytrium dendrobatidis, is associated with recent declines in amphibian populations. Susceptibility to this disease varies among amphibian populations and species, and resistance appears to be attributable in part to the presence of antifungal microbial species associated with the skin of amphibians. The betaproteobacterium Janthinobacterium lividum has been isolated from the skins of several amphibian species and produces the antifungal metabolite violacein, which inhibits B. dendrobatidis. In this study, we added J. lividum to red-backed salamanders (Plethodon cinereus) to obtain an increased range of violacein concentrations on the skin. Adding J. lividum to the skin of the salamander increased the concentration of violacein on the skin, which was strongly associated with survival after experimental exposure to B. dendrobatidis. As expected from previous work, some individuals that did not receive J. lividum and were exposed to B. dendrobatidis survived. These individuals had concentrations of bacterially produced violacein on their skins that were predicted to kill B. dendrobatidis. Our study suggests that a threshold violacein concentration of about 18 microM on a salamander's skin prevents mortality and morbidity caused by B. dendrobatidis. In addition, we show that over one-half of individuals in nature support antifungal bacteria that produce violacein, which suggests that there is a mutualism between violacein-producing bacteria and P. cinereus and that adding J. lividum is effective for protecting individuals that lack violacein-producing skin bacteria.
Becker
Matthew H
MH
Department of Biological Sciences, Virginia Tech, MC 0406, Blacksburg, VA 24061, USA. mhbecker3@gmail.com
Brucker
Robert M
RM
Schwantes
Christian R
CR
Harris
Reid N
RN
Minbiole
Kevin P C
KP
D000818:Animals; D000935:Antifungal Agents / Q000378:metabolism / Q000494:pharmacology*; D008411:Chytridiomycota / Q000187:drug effects* / Q000302:isolation & purification; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology*; D009181:Mycoses / Q000382:microbiology / Q000401:mortality / Q000662:veterinary*; D042802:Oxalobacteraceae / Q000254:growth & development / Q000378:metabolism*; D012867:Skin / Q000737:chemistry / Q000382:microbiology; D016019:Survival Analysis; D014562:Caudata / Q000382:microbiology*
D000935:Antifungal Agents; D007211:Indoles; C063155:violacein